Knowing this timeline eliminates the psychological reaction of thinking something has gone wrong when velocity slows in the final months
But with the obesity market still early in its global adoption curve, 18.9% growth looks conservative rather than ambitious
Other options may be preferable for people who: Prefer FDA-approved finished drug products: If having an FDA-approved finished product is important to you, compounded formulations - from any platform - may not align with your preferences
The medical literature on GLP-1 receptor agonists reveals an uncomfortable truth: without intervention, a substantial portion of rapid weight loss comes from lean tissue
So far, studies have reported: Phase 2 (48 weeks): up to 24.2% average weight loss Phase 3 TRIUMPH-4 topline (68 weeks): 28.7% average weight loss (press release) What that looks like: If you start at 100 kg : 24.2% 24 kg average loss 28.7% 29 kg average loss Side effects and safety signals (what we know so far) Phase 2 (peer-reviewed) In the phase 2 trial, the most common adverse events were gastrointestinal and dose-related, typically mild to moderate
While these metabolic changes can improve overall health, they may also influence the hair growth cycle
